The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii

Shawn R. Lockhart; Annette W. Fothergill; Naureen Iqbal; Carol B. Bolden; Nina T. Grossman; Edward P. Garvey; Stephen R. Brand; William J. Hoekstra; Robert J. Schotzinger; Elizabeth Ottinger; Thomas F. Patterson; Nathan P. Wiederhold

doi:10.1128/AAC.02770-15

The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii

Shawn R. Lockhart, Annette W. Fothergill, Naureen Iqbal, Carol B. Bolden, Nina T. Grossman, Edward P. Garvey, Stephen R. Brand, William J. Hoekstra, Robert J. Schotzinger, Elizabeth Ottinger, Thomas F. Patterson, Nathan P. Wiederhold

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

The in vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of Cryptococcus neoformans and Cryptococcus gattii isolates. VT-1129 demonstrated potent activities against both Cryptococcus species as demonstrated by low MIC₅₀and MIC₉₀values. For C. gattii, the in vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against C. neoformans, including isolates with reduced fluconazole susceptibility.

Original language	English (US)
Pages (from-to)	2528-2531
Number of pages	4
Journal	Antimicrobial agents and chemotherapy
Volume	60
Issue number	4
DOIs	https://doi.org/10.1128/AAC.02770-15
State	Published - Apr 2016

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.02770-15

Fingerprint Dive into the research topics of 'The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii'. Together they form a unique fingerprint.

Cite this

Lockhart, S. R., Fothergill, A. W., Iqbal, N., Bolden, C. B., Grossman, N. T., Garvey, E. P., Brand, S. R., Hoekstra, W. J., Schotzinger, R. J., Ottinger, E., Patterson, T. F., & Wiederhold, N. P. (2016). The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii. Antimicrobial agents and chemotherapy, 60(4), 2528-2531. https://doi.org/10.1128/AAC.02770-15

The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii. / Lockhart, Shawn R.; Fothergill, Annette W.; Iqbal, Naureen; Bolden, Carol B.; Grossman, Nina T.; Garvey, Edward P.; Brand, Stephen R.; Hoekstra, William J.; Schotzinger, Robert J.; Ottinger, Elizabeth; Patterson, Thomas F.; Wiederhold, Nathan P.

In: Antimicrobial agents and chemotherapy, Vol. 60, No. 4, 04.2016, p. 2528-2531.

Research output: Contribution to journal › Article › peer-review

Lockhart, SR, Fothergill, AW, Iqbal, N, Bolden, CB, Grossman, NT, Garvey, EP, Brand, SR, Hoekstra, WJ, Schotzinger, RJ, Ottinger, E, Patterson, TF & Wiederhold, NP 2016, 'The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii', Antimicrobial agents and chemotherapy, vol. 60, no. 4, pp. 2528-2531. https://doi.org/10.1128/AAC.02770-15

Lockhart, Shawn R. ; Fothergill, Annette W. ; Iqbal, Naureen ; Bolden, Carol B. ; Grossman, Nina T. ; Garvey, Edward P. ; Brand, Stephen R. ; Hoekstra, William J. ; Schotzinger, Robert J. ; Ottinger, Elizabeth ; Patterson, Thomas F. ; Wiederhold, Nathan P. / The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii. In: Antimicrobial agents and chemotherapy. 2016 ; Vol. 60, No. 4. pp. 2528-2531.

@article{dd155ac633bf4cfd95de184b124860d0,

title = "The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii",

abstract = "The in vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of Cryptococcus neoformans and Cryptococcus gattii isolates. VT-1129 demonstrated potent activities against both Cryptococcus species as demonstrated by low MIC50and MIC90values. For C. gattii, the in vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against C. neoformans, including isolates with reduced fluconazole susceptibility.",

author = "Lockhart, {Shawn R.} and Fothergill, {Annette W.} and Naureen Iqbal and Bolden, {Carol B.} and Grossman, {Nina T.} and Garvey, {Edward P.} and Brand, {Stephen R.} and Hoekstra, {William J.} and Schotzinger, {Robert J.} and Elizabeth Ottinger and Patterson, {Thomas F.} and Wiederhold, {Nathan P.}",

note = "Funding Information: This project was funded by the National Institutes of Health National Institute of Allergy and Infectious Diseases under contract no. N01-AI-25475 (Thomas F. Patterson), the National Institutes of Health, National Center for Advancing Translational Sciences, Therapeutics for Rare and Neglected Diseases (TRND) Program (Shawn R. Lockhart), and Viamet Pharmaceuticals, Inc. (Nathan P. Wiederhold). VT-1129 powder was provided by Viamet Pharmaceuticals, Inc.",

year = "2016",

month = apr,

doi = "10.1128/AAC.02770-15",

language = "English (US)",

volume = "60",

pages = "2528--2531",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "4",

}

TY - JOUR

T1 - The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii

AU - Lockhart, Shawn R.

AU - Fothergill, Annette W.

AU - Iqbal, Naureen

AU - Bolden, Carol B.

AU - Grossman, Nina T.

AU - Garvey, Edward P.

AU - Brand, Stephen R.

AU - Hoekstra, William J.

AU - Schotzinger, Robert J.

AU - Ottinger, Elizabeth

AU - Patterson, Thomas F.

AU - Wiederhold, Nathan P.

N1 - Funding Information: This project was funded by the National Institutes of Health National Institute of Allergy and Infectious Diseases under contract no. N01-AI-25475 (Thomas F. Patterson), the National Institutes of Health, National Center for Advancing Translational Sciences, Therapeutics for Rare and Neglected Diseases (TRND) Program (Shawn R. Lockhart), and Viamet Pharmaceuticals, Inc. (Nathan P. Wiederhold). VT-1129 powder was provided by Viamet Pharmaceuticals, Inc.

PY - 2016/4

Y1 - 2016/4

N2 - The in vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of Cryptococcus neoformans and Cryptococcus gattii isolates. VT-1129 demonstrated potent activities against both Cryptococcus species as demonstrated by low MIC50and MIC90values. For C. gattii, the in vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against C. neoformans, including isolates with reduced fluconazole susceptibility.

AB - The in vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of Cryptococcus neoformans and Cryptococcus gattii isolates. VT-1129 demonstrated potent activities against both Cryptococcus species as demonstrated by low MIC50and MIC90values. For C. gattii, the in vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against C. neoformans, including isolates with reduced fluconazole susceptibility.

UR - http://www.scopus.com/inward/record.url?scp=84963717381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963717381&partnerID=8YFLogxK

U2 - 10.1128/AAC.02770-15

DO - 10.1128/AAC.02770-15

M3 - Article

C2 - 26787697

AN - SCOPUS:84963717381

VL - 60

SP - 2528

EP - 2531

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -